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ABSTRACT         ARTICLE INFO______________________________________________________________     ______________________
The present study describes the histopathological and molecular effects of P-MAPA 
(Protein aggregate magnesium-ammonium phospholinoleate-palmitoleate anhydride) 
intravesical immunotherapy combined with systemic doxorubicin or cisplatin for treat-
ment of non-muscle invasive bladder cancer (NMIBC) in an appropriate animal model. 
Our results showed an undifferentiated tumor, characterizing a tumor invading mucosa 
or submucosa of the bladder wall (pT1) and papillary carcinoma in situ (pTa) in the 
Cancer group. The histopathological changes were similar between the combined treat-
ment with intravesical P-MAPA plus systemic Cisplatin and P-MAPA immunotherapy 
alone, showing decrease of urothelial neoplastic lesions progression and histopatholo-
gical recovery in 80% of the animals. The animals treated systemically with cisplatin or 
doxorubicin singly, showed 100% of malignant lesions in the urinary bladder. Furthe-
more, the combined treatment with P-MAPA and Doxorubicin showed no decrease of 
urothelial neoplastic lesions progression and histopathological recovery. Furthermore, 
Akt, PI3K, NF-kB and VEGF protein levels were significantly lower in intravesical 
P-MAPA plus systemic cisplatin and in intravesical P-MAPA alone treatments than 
other groups. In contrast, PTEN protein levels were significantly higher in intravesical 
P-MAPA plus systemic cisplatin and in intravesical P-MAPA alone treatments. Thus, 
it could be concluded that combination of intravesical P-MAPA immunotherapy and 
systemic cisplatin in the NMIBC animal model was effective, well tolerated and showed 
no apparent signs of antagonism between the drugs. In addition, intravesical P-MAPA 
immunotherapy may be considered as a valuable option for treatment of BCG unres-
ponsive patients that unmet the criteria for early cystectomy.
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INTRODUCTION
The primary treatment for high grade non-
muscle invasive bladder cancer (NMIBC) is based 
on surgery by Transurethral Resection of Bladder 
Tumor (TURBT), followed by intravesical immu-
notherapy with Bacillus Calmette-Guerin (BCG) 
to prevent recurrence and reduct the tumor pro-
gression (1). However, undesirable side events re-
lated with BCG therapy are observed up to 90% 
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of patients and range from cystitis and irritative 
voiding symptoms to major complications such as 
sepsis and death related to the treatment (2).
Although TURBT plus intravesical BCG are 
the standard treatment for high grade NMIBC, in-
travesical chemotherapies are currently used after 
TURBT for adjuvant treatment of low grade NMIBC 
and also in some occasions for treatment of high 
grade NMIBC, in the case of BCG fail and finally 
as a recover therapy for patients that are ineligible 
for cystectomy. Mitomycin C (MMC), Doxorubicin, 
Valrubicin, Epirubicin, Thiotepa, Docetaxel, Gem-
citabine, are the most used chemotherapy drugs 
for this goal (3).
Doxorubicin (DOXO), another component 
frequently used in Cisplatin-based regimens, is 
an antineoplastic drug of the anthracycline fam-
ily that inhibits Topoisomerase II (4). DOXO is in-
dicated for treatment of various cancers such as 
acute lymphoblastic leukemia, acute myeloid leu-
kemia, transitional cell bladder carcinoma, breast 
carcinoma, neuroblastoma, Wilms tumor, ovar-
ian carcinoma, thyroid carcinoma, prostate car-
cinoma, Hodgkin and non-Hodgkin lymphomas, 
sarcomas and Ewing sarcoma. DOXO has shown 
cardiotoxicity and can cause serious heart prob-
lems or life threatening. Moreover, it can cause 
a sharp decrease in the number of blood cells in 
bone marrow and an increase in the risk of leu-
kemia (5).
Since the discovery of the biological ac-
tivity of cisplatin [cis-diammine-dichloroplatinum 
(II)] the interest in anticancer drugs based on met-
als has for treatment of solid tumors has increased 
(6). Cisplatin forms a Platinum-DNA adducts at 
the N7 position of guanine, leading to intrachain 
crosslinkings 1, 2-d (GpG) and 1, 2-d (ApG) and 
interchain links, so activating proteins in response 
to injury. The proteins, in turn, inhibit cyclin-de-
pendent kinase (CDK) and finally the cells undergo 
apoptosis via p53 (7).
Taking into account that bladder cancer 
(BC) is sensitive to both immunotherapies and 
chemotherapies, compounds that activate the im-
mune system, including vaccines, biological re-
sponse modifiers, tumor environment modulators 
of steroid hormones, can be considered potential 
candidates for the development of new treatments 
of BC to be used alone or in combination with 
systemic chemotherapies aiming to obtain greater 
therapeutic effect combined with lower toxicity. 
In animal models for study of cancer, P-MAPA 
(Protein aggregate magnesium-ammonium phos-
pholinoleate-palmitoleate anhydride), a biological 
response modifier developed by Farmabrasilis - 
a non-profit research network, obtained by fer-
mentation from Aspergillus oryzae, has shown an 
ability to reverse the state of immunosuppression 
caused by tumoral processes, and such effect is 
linked to a significant therapeutic impact in the 
primary disease combined with low toxicity (8, 9).
Thus, the aims of this study were to evalu-
ate and to compare P-MAPA intravesical immuno-
therapy in association with systemic chemothera-
pies (Doxorubicin and Cisplatin) for treatment of 
NMIBC in an appropriate animal model.
MATERIALS AND METHODS
Experimental Proceedings
Thirty-five female Fischer 344 strain 
rats, all 7 weeks old, with an average weight of 
150grams, were provided by Multidisciplinary 
Center for Biological Investigation (CEMIB) at 
University of Campinas (UNICAMP). For induction 
of NMIBC, 30 animals were considered as Can-
cer group and anesthetized with 10% ketamine 
(60mg/kg, i.m.; Vibra® Roseira, São Paulo, Brazil) 
and 2% xylazine (5mg/kg, i.m.; Vibra® Roseira, 
São Paulo, Brazil), held in this state for 45 minutes 
to avoid spontaneous urination and administered 
1.5mg/Kg dose of n-methyl-n-nitrosourea (MNU) 
dissolved in 0.30mL of sodium citrate (1M pH 6.0); 
every one via a 22-gauge angiocatheter intravesi-
cally every other week for 8 weeks (8, 9). The other 
5 animals were considered as Control group. Two 
weeks after the last dose of MNU the occurrence 
of tumor was evaluated by cystography, as well 
as, considered clinical criteria such as haematu-
ria and weight loss. Subsequently, the animals 
were divided into 7 groups (5 animals per group): 
Group 1 (Control): received 0.30mL dose of 0.9% 
physiological saline intravesically every other 
week for 6 weeks; Group 2 (MNU – Cancer): re-
ceived the same treatment as the Group 1; Group 3 
(MNU+P-MAPA): received 5mg/kg dose of P-MA-
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PA (Farmabrasilis, Campinas, SP, Brazil) intravesi-
cally every other week for 6 weeks (8, 9); Group 4 
(MNU+Cisplatin): received 0.25mg/kg dose of cis-
platin (Intas Pharmaceuticals, Ahmedabad, India) 
intraperitoneal, once per week for 4 consecutive 
weeks (10); Group 5 (MNU+Doxorubicin): received 
3mg/kg dose of pegylated liposomal doxorubicin 
(Janssen, Johnson & Johnson, Horsham, PA, USA), 
intraperitoneal, every 15 days for 4 consecutive 
weeks (11); Group 6 (MNU+Cisplatin+P-MAPA): 
received concurrent treatment with P-MAPA and 
cisplatin at the same concentrations and the same 
routes of administration as Groups 3 and 4; Group 
7 (MNU+Doxorubicin+P-MAPA): received concur-
rent treatment with P-MAPA and doxorubicin at 
the same concentrations and routes of administra-
tion as groups 3 and 5.
After 16 weeks of treatment, the animals 
were euthanized and their urinary bladder was 
collected and processed for histopathological and 
Western Blotting analyses.
The animal experiments described here 
were performed in accordance with the guide-
lines of the Brazilian College for Animal Experi-
mentation (COBEA) and the guidelines set forth 
by our Institution (protocol number: CEUA/UNI-
CAMP#3645-1).
Histopathological Analysis
For histopathological analysis, fragments 
of urinary bladders were randomly collected from 
all animals in each group, fixed by immersion in 
Bouin, embedded in plastic polymer (Paraplast 
Plus; Sigma Chemical Co., St. Louis, MO, USA) cut 
into 5-μm thick and stained with hematoxylin-eo-
sin. The neoplastic lesions were diagnosed using 
the nomenclature proposed by the World Health 
Organization/International Society of Urological 
Pathology consensus classification (12).
Western Blotting Analysis: Akt (Protein kinase 
B), NF-kB (nuclear factor kappa-light-chain-
enhancer of activated B cells), PI3K (phospha-
tidylinositol-3-kinase), PTEN (Phosphatase and 
tensin homolog) and VEGF (Vascular endothelial 
growth factor)
Fragments of the urinary bladders were col-
lected from 5 animals in each group, frozen in liquid 
nitrogen, weighed and homogenized in 50μL/mg 
of RIPA lysis buffer (EMD Millipore Corporation, 
Billerica, MA, USA). The tissue homogenized was 
centrifuged, and a sample of each extract was used 
for protein quantification by Bradford’s method. 
Aliquots containing 70μg of protein were separat-
ed by SDS-PAGE on 10% or 12% polyacrylamide 
gels under reducing conditions. After electropho-
resis, the proteins were transferred to nitrocellulose 
membranes and blocked with TBS-T containing 
1% BSA (bovine serum albumin) and incubated 
at 4°C overnight with primary mouse monoclonal 
antibody sc-5298 (Santa Cruz Biotechnology, TX, 
USA) specific for Akt, rabbit polyclonal ab7970 
(abcam, MA, USA) specific for NF-kB, rabbit poly-
clonal sc-67306 (Santa Cruz Biotechnology, TX, 
USA) specific for PI3K, rabbit monoclonal 138G6 
(Cell Signaling, MA, USA) specific for PTEN and 
mouse monoclonal sc-53462 (Santa Cruz Biotech-
nology, TX, USA) specific for VEGF diluted in 1% 
BSA. The membranes were then incubated for 2h 
with anti-rabbit and anti-mouse secondary HRP-
conjugated antibodies (diluted 1:3.000 in 1% BSA; 
Santa Cruz Biotechnology, TX, USA). Peroxidase’s 
activity was detected by incubation with a diami-
nobenzidine chromogen. Western blots were run in 
duplicate, and urinary bladder samples were pooled 
from 5 animals per group for each repetition (10). 
The semi-quantitative densitometry (IOD - Inte-
grated Optical Density) analysis of bands was con-
ducted using NIH ImageJ 1.47v software (National 
Institute of Health, USA. Available in: http://rsb.
info.nih.gov/ij/), followed by statistical analysis. 
β-actin (mouse monoclonal sc-47778, Santa Cruz 
Biotechnology, TX, USA) was used as endogenous 
positive controls for standardization of the read-
ings of the band’s staining intensity. The results 
were expressed as the mean±standard deviation of 
the ratio of each band’s intensity to β-actin band 
intensity (9).
Statistical analysis
For the statistical analysis, an analysis of vari-
ance (ANOVA) was used followed by Tukey’s test for 
comparison of means. All analyses were performed 
with a significance level of P<0.01. The results were 
expressed as the mean±standard deviation.
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RESULTS
Macroscopic Analysis: body weight
The animals of the Group 2 (MNU - Can-
cer) showed a significant reduction in body weight 
when compared to other groups (Graph 1). In con-
trast, the animals of Groups 3, 4, 5, 6 and 7 showed 
no reduction in body weight when compared with 
Group 1 (Graph 1).
Histopathological Analysis
The animals of Group 1 did not show 
structural changes in their urinary tract, keeping 
the urothelium, formed by 2 - 3 layers, i.e., one 
basal cell layer, an intermediate cell layer, and 
a apical surface layer (Figure-1a). The Group 2 
showed relevant structural changes such as hy-
dronephrosis and hydroureter in the urinary tract; 
histopathological analysis of the urinary bladder 
of these animals showed tumor invading mucosa 
or submucosa of the bladder wall (pT1) in 20% 
and papillary carcinoma in situ (pTa) in 80% of 
animals (Figures 1b and 1c; Table-1).
The animals of Group 3 showed decrease 
of urothelial neoplastic lesions progression. Pap-
illary hyperplasia (Figures 1d and 1e; Table-1), 
characterized by thickening of urothelium with 
no cytologic atypia was the most frequent lesion 
observed in 80% of animals; whereas pTa was ob-
served in 20% of animals (Table-1).
After cisplatin treatment, the animals of 
Group 4 showed major structural changes in their 
urinary tract, such as hickening of the urinary 
bladder wall, increased urinary bladder vascular-
ization and nodular lesions in the kidneys. The 
most frequent histopathological changes in the 
urinary bladder from this group were flat carcino-
ma in situ (pTis) (Figure 1f; Table-1), pTa (Figure 
1g; Table-1) and pT1 in 60%, 20% and 20% of the 
animals, respectively (Table-1).
The animals treated with doxorubicin 
(Group 5) showed pTa (80%) with inflammatory 
infiltrate in the lamina propria (Figures 2a and 
2b; Table-1) and 20% showed flat hyperplasia 
(Table-1). In addition, structural changes on the 
urinary tract as necrotic lesions in the kidneys 
and bilateral hydroureter were observerd in 80% 
of the animals.
Animals treated with P-MAPA associated 
to Cisplatin (Group 6) clearly showed better histo-
pathological recovery from the cancer state than 
Group 1 (Control); Group 2 (MNU – Cancer); Group 3 (MNU+PMAPA); Group 4 (MNU+Cisplatin); Group 5 (MNU+Doxorubicin); Group 6 (MNU+Cisplatin+PMAPA) 
and Group 7 (MNU+Doxorubicin + PMAPA).
* = Significant difference (P < 0.05) compared to Group 2.
Graph 1 - Body weight of the seven experimental groups.
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Figures 1a – 1g: Photomicrographs of the most frequent histopathological changes in the urinary bladder of Control (a), MNU 
– Cancer (b, c), MNU+PMAPA (d, e) and MNU+Cisplatin (f, g) groups. (a) Normal urothelium, composed of 2-3 layers: a layer 
of basal cells, an intermediate layer of cells and a surface layer composed of apical or umbrella cells. (b, c) Tumor invading 
mucosa or submucosa of the bladder wall (pT1): neoplastic cells arranged in small groups (arrows) invading the lamina propria. 
(d, e) Papillary hyperplasia, characterized by thickening of the urothelium in the absence of cytologic atypia. (f) Flat carcinoma 
in situ (pTis) characterized by a disorderly proliferation of urothelial cells with cytologic atypia. (g) Papillary carcinoma in situ 
(pTa) characterized by extensive papillary lesions, urothelial cells with disordered arrangement and loss of polarity. 
A
C
E
G
B
D
F
a-g: Lp = lamina propria; Ur = urothelium. 
All figures were staining with hematoxylin and eosin.
182x289mm (300 x 300 DPI)
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those observed on the Groups 3 and 4, showing 
decrease of urothelial neoplastic lesions progres-
sion in 80% of the animals (Figures 2c, 2d, 2e; 
Table-1). In contrast, the animals treated with cis-
platin alone (Group 4) showed 100% of malignant 
lesions (Table-1). Normal urothelium was found 
in 20% of the animals from Group 6 (Figure-2e). 
The histopathological changes in this group were 
flat hyperplasia (Figure-2c), papillary hyperplasia 
(Figure-2d) and pTa in 40%, 20% and 20% of the 
animals, respectively (Table-1).
All animals from Group 7 
(MNU+Doxorubicin+P-MAPA) showed 100% of 
(pTa) with squamous metaplasia associated (Fig-
ures 2f, 2g, 2h; Table-1).
Western Blotting Analysis: Akt, NF-kB, PI3K, 
PTEN and VEGF
The lowest Akt protein levels were found 
in the Groups 1 and 6 (Figure-3a) when compared 
to other experimental groups, which were signifi-
cantly higher for this protein (Figure-3a). NF-kB 
protein levels were significantly higher in the 
Groups 5 and 7 than in the other experimental 
groups (Figure-3b). Also, these levels were numer-
ically lower in the Group 6 in relation to Groups 
1, 2, 3 and 4 (Figure-3b).
The highest PTEN protein levels were found 
in the Groups 1, 3 and 6 in relation to other ex-
perimental groups, which were significantly lower 
for this protein (Figure-3c). In contrast, PI3K pro-
tein levels were significantly higher in the Groups 
4 and 5 in relation to other experimental groups 
(Figure-3d).
VEGF protein levels were considerably 
lower in the Groups 1, 6 and 7 in relation to other 
experimental groups (Figure-4). In addition, these 
levels were numerically lower in the Group 3 in 
relation to Groups 2, 4 and 5 (Figure-4).
DISCUSSION AND CONCLUSIONS
In this work, the histopathological results 
showed undifferentiated tumor, characterizing tu-
mor invading mucosa or submucosa of the bladder 
wall (pT1) and papillary carcinoma in situ (pTa) 
in the MNU group, demonstrating that MNU was 
effective to induce NMIBC in this animal model. 
The P-MAPA intravesical immunotherapy alone 
led to a histopathological recovery and decrease 
of urothelial neoplastic lesions progression in 80% 
of the animals. The animals treated with systemic 
cisplatin or doxorubicin singly, showed drastic 
changes in the urinary tract, such as thickening of 
the urinary bladder wall, increased urinary blad-
der vascularization and nodular lesions on the 
kidneys, as well as, 100% of malignant lesions in 
the urinary bladder.
The groups that received P-MAPA intravesi-
cal immunotherapy combined to systemic therapies 
based on Cisplatin or Doxorubicin showed differ-
ent results when compared to groups that received 
Table 1 - Percentage of histopathological changes in the urinary bladder of the seven experimental groups.
Urothelial lesions Group 1
(n=5)
Group 2
(n=5)
Group 3
(n=5)
Group 4
(n=5)
Group 5
(n=5)
Group 6
(n=5)
Group 7
(n=5)
No lesion Normal Urothelium 100% (5) _ _ _ _ 20% (1) _
Benign 
lesions
Flat Hyperplasia _ _ _ _ 20% (1) 40% (2) _
Papillary Hyperplasia _ _ 80% (4) _ _ 20% (1) _
Flat Carcinoma in situ (pTis) _ _ _ 60% (3) _ _ _
Malign 
lesions
Papillary Carcinoma in situ 
(pTa)
_ 20% (1) 20% (1) 20% (1) 80% (4) 20% (1) 100% (5)
Tumor invading mucosa or 
submucosa of the bladder 
wall (pT1)
_ 80% (4) _ 20% (1) _ _ _
Group 1 (Control); Group 2 (MNU-Cancer); Group 3 (MNU+P-MAPA); Group 4 (MNU+Cisplatin); Group 5 (MNU+Doxorubicin); Group 6 (MNU+Cisplatin+P-MAPA) 
and Group 7 (MNU+Doxorubicin+P-MAPA).
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Figures 2a – 2h: Photomicrographs of the most frequent histopathological changes in the urinary bladder of MNU+Doxorubicin 
(a, b), MNU+Cisplatin+P-MAPA (c, d, e) and MNU+ Doxorubicin+P-MAPA (f, g, h) groups. (a, f, g, h) Papillary carcinoma in 
situ (pTa). (b) pTa with inflammatory infiltrate in the lamina propria. (c) Flat hyperplasia characterized by thickening of the 
urothelium and absence of cytologic atypia. (d) Papillary hyperplasia. (e) Normal urothelium, similar to that shown in the 
Control group.
a-h: Lp = lamina propria, Ur = urothelium.
All figures were staining with hematoxylin and eosin.
182x291mm (300 x 300 DPI)
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Figures 3a – 3d: Western Blotting and semi quantitative determination of Akt (a), NF-kB (b), PTEN (c) and PI3K (d) protein 
levels. The protein levels were identified from the blots. β-Actin (42 kDa) was used as the internal control. Group 1 
(Control), Group 2 (MNU – Cancer), Group 3 (MNU+PMAPA), Group 4 (MNU+Cisplatin), Group 5 (MNU+Doxorubicin), Group 
6 (MNU+Cisplatin+PMAPA) and Group 7 (MNU+Doxorubicin+PMAPA). Data are expressed as the mean ± standard deviation 
(n= 5). Different lowercase letters (a, b, c, d) indicate significant differences (P < 0.01) between the groups after Tukey’s test. 
Molecular weight: Akt (62 kDa), NF-kB (64 kDa), PTEN (54 kDa) and PI3K (190 kDa).
227x265mm (300 x 300 DPI)
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the same therapies administered singly. The his-
topathological changes were similar between in-
travesical P-MAPA plus systemic Cisplatin and 
intravesical P-MAPA alone treatments, showing 
decrease of urothelial neoplastic lesions progres-
sion and histopathological recovery in 80% of 
the animals. In contrast, systemic treatments 
with Cisplatin or Doxorubicin singly showed 
100% of malignant lesions. Furthemore, the com-
bined treatment with P-MAPA and Doxorubicin 
showed no decrease of urothelial neoplastic le-
sions progression and histopathological recovery.
BCG is the standard adjuvant treatment 
for high-grade NMIBC, and the only approved 
drug able to avoid or at least retard the progres-
sion to invasive disease (1). Despite therapeutic 
use of BCG for Tis and its adjuvant use for high-
grade Ta or T1, disease recurrence occurs in up to 
50% of patients (13). In addition, for Tis patients 
who are BCG non-responders the risk of progres-
sion is up to 90% at 6 months of treatment (13).
Following episodes of high grade NMIBC 
recurrence after BCG therapy, several conven-
tional chemotherapy agents have been used 
including thiothepa, gemcitabine, mitomycin, 
gemcitabine plus mitomycin, docetaxel and val-
rubicin. In addition, immunotherapy (Interferon-
alpha or Interferon alpha-plus BCG) has also 
been used (13). Mycobacterium phlei cell wall-
nucleic acid complex (MCNA) has been proposed 
for intravesical treatment of NMIBC at high risk 
of recurrence or progression in patients who 
failed prior BCG immunotherapy (e.g., in patients 
who are BCG-refractory or BCG relapsing) and 
are not candidates for or refuse cystectomy (14). 
However, none of these drugs had been shown 
superiority over BCG and remains considered in-
vestigational (14). In the specific case of BCG-
refractory CIS, Valrubicin, a semi-syntetic analog 
of doxorubicin, the only FDA-approved drug for 
treatment of such condition, shows effectivity in 
less of 10% of treated patients at 2 years and 
none with coincident stage T1 disease (15).
Therefore, the recommended standard of 
care for patients with recurrent high-grade dis-
ease after optimal BCG treatment has been to 
proceed with cystectomy (3, 16). However, pa-
tients who refuse or are unfit for bladder removal 
face an increased risk of progression to muscle-
invasive disease (3, 16). No approved drug pre-
senting similar or superior outcomes than BCG 
are available for treatment of this condition.
For treatment of invasive bladder cancer 
using a combination of TURBT, radiation thera-
py, and systemic chemotherapy-trimodality blad-
der preservation therapy-has been proposed and 
used in the last years for treatment of carefully 
selected patients (17). Also, the National Compre-
hensive Cancer Network Clinical Practice Guide-
lines in Oncology for Bladder Cancer and the 
International Consultation on Urological Diseas-
es-European Association of Urology recognized 
the trimodality preservation bladder therapy as 
an alternative to radical cystectomy for patients 
with MIBC who are noncystectomy candidates 
Figure 4 - Western Blotting and semi quantitative 
determination of VEGF protein levels. The protein levels were 
identified from the blots. β-Actin (42 kDa) was used as the 
internal control. Group 1 (Control), Group 2 (MNU – Cancer), 
Group 3 (MNU+PMAPA), Group 4 (MNU+Cisplatin), Group 5 
(MNU+Doxorubicin), Group 6 (MNU+Cisplatin+PMAPA) and 
Group 7 (MNU+Doxorubicin+PMAPA). Data are expressed as 
the mean ± standard deviation (n= 5). Different lowercase 
letters (a, b, c, d) indicate significant differences (P < 0.01) 
between the groups after Tukey’s test. Molecular weight: 
VEGF (30 kDa).
113x120mm (300 x 300 DPI)
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and for those that are motivated to keep their 
native bladders (18). Despite the advances in the 
development of systemic chemotherapy regi-
mens, the treatment of invasive and metastatic 
bladder cancer remains a big challenge, due the 
presence of toxicities associated with treatments 
as well the low rates of long-time survival for 
patients that present these conditions. Therefore, 
the need of development of new regimes, which 
provide better survival outcomes or similar sur-
vival with reduced toxicity, continues.
Although combinations of chemothera-
pies is the more frequent choice for the elabo-
ration of treatment regimens for advanced and 
metastatic urothelial disease, the combination of 
chemotherapies with immunotherapies is also a 
possible approach to be used for the treatment 
of patients that are unfit for cystectomy as well 
for those presenting inoperable locally advanced 
and metastatic urothelial cancer and finally for 
the occasions that despite the presence of inva-
sive disease an organ-conservative strategy may 
be used. For this reason while P-MAPA shows 
antitumor effects in animal model when used 
systemically in some types of cancer, such as Eh-
rlich ascitic tumor (19) and prostate cancer (20) 
in these studies our research group evaluate the 
drug candidate by intravesical via combined with 
systemic chemotherapy aiming to investigate the 
effects of such combination on NMIBC and also 
the possibility of its effect on the treatment of 
advanced or metastatic BC under a bladder pres-
ervation approach.
The reason for the selection of Cisplatin 
and DOXO for combined use with P-MAPA, by 
our research group is based on the knowledge 
that the main combinations developed to treat 
invasive or metastatic bladder cancer are cispla-
tin-based (21), such as the combination of meth-
otrexate, vinblastine, doxorubicin, and cispla-
tin (MVAC). Developed some years ago (21) the 
combination MVAC remains until now the most 
used for the treatment of invasive and metastatic 
bladder cancer.
Cisplatin plus Gemcitabine is another 
cisplatin-based combination in advanced stage 
of development. Using such combination, a ran-
domized phase III study enrolling patients with 
locally advanced or metastatic transitional cell 
carcinoma (TCC) of the urothelium indicates 
that the combination (GC) is an effective al-
ternative to MVAC therapy presenting similar 
clinical efficacy with a better tolerability and 
safety profile (22).
Currently, DOXO can be administered in-
travenously at a 2mg/mL dose or intravesically 
at a 1mg/mL dose. The intravesical route of ad-
ministration is used to treat monocytic carci-
noma, papillary bladder tumors and carcinoma 
in situ to reduce recurrences after transurethral 
resection (5). However, administration of DOXO 
intravesical, though reducing adverse effects 
compared to intravenous administration, has low 
efficiency, and there is recurrence of tumor in 
80% of cases. Taking in account that the mech-
anism of action of P-MAPA involves an inter-
feron signaling pathway (9) in view of a study 
(23) showing a significant decrease of Interfer-
on-gamma and IL-2 levels induced by Con A in 
splenocytes of doxorubicin treated mice, a hy-
pothesis to be investigate, is that the systemic 
DOXO may depressed the IFN-gamma levels on 
treated animals, that may impaired the effects of 
P-MAPA.
In this work, Western Blotting analy-
ses showed a decrease statistically signifi-
cant in Akt, PI3K and NF-kB protein levels in 
MNU+Cisplatin+P-MAPA and MNU+P-MAPA 
groups in relation to other experimental groups. 
In contrast, PTEN protein levels were significant 
higher in MNU+Cisplatin+P-MAPA and MNU+P-
MAPA groups than other experimental groups.
The PI3K/Akt/mTOR is a major intracellu-
lar signaling pathway responsible for promoting 
cell survival and proliferation (24). This pathway 
is initiated by PI3K enzyme, which is activated 
by tyrosine kinases or G-protein coupled recep-
tors (24). PTEN protein acts as a phosphatase to 
dephosphorylate phosphatidylinositol (3-5) - tri-
sphosphate (PtdIns (3-5) P3 or PIP3). PTEN spe-
cifically catalyses the dephosporylation of the 3` 
phosphate of the inositol ring in PIP3, resulting 
in the biphosphate product PIP2 (PtdIns (4, 5) 
P2) (24). This dephosphorylation is important be-
cause it results in inhibition of the PI3K and AKT 
signaling pathways, which can act as oncogenes 
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for promoting cell survival (25). Akt activation 
leads to anti-apoptotic events and induces cell 
proliferation, which promotes carcinogenesis (26).
PTEN expression also induces apoptosis 
and suppresses cell growth through activation 
of caspase-3 and suppression of NF-kβ (27). NF-
kB signaling pathway plays an important role in 
the responses to cancer, inflammation and stress 
(28). NF-kB is a transcription factor found in 
the cytoplasm bound to known NF-kB inhibi-
tors (IκB). The activation of NF-kB by inflamma-
tory and growth factors is mediated through the 
protein IκB kinases (IKKS), which phosphorylate 
IκB, resulting in ubiquitination and subsequent 
proteasomal degradation of IκBα (28). The wide 
distribution of NF-kB binding sites in the ge-
nome allows the regulation of a large number of 
genes and participates on fundamental cellular 
processes, such as apoptosis, proliferation, and 
differentiation (28).
Thus, it could be concluded that the as-
sociation between P-MAPA intravesical immu-
notherapy and chemotherapeutic agents, espe-
cially cisplatin, promoted a reduction of PI3K/
Akt pathway activation and stimulated PTEN 
pathway, which led to reduced NF-kB levels with 
consequent decrease of proliferation of urothelial 
tumor cells.
Angiogenesis is a central process to tumor 
progression (29). VEGF is one of the key regulators 
of angiogenesis and the prime target of antiangio-
genic drug development for the treatment of mul-
tiple cancers (29). Also, VEGF protects tumor cells 
against chemotherapy-induced apoptosis (29, 30). 
Therefore, the relative over expression of VEGF ob-
served within the residual tumors after MVAC may 
reflect the clonal selection resulting from the death 
of tumor cells expressing low levels of VEGF and 
the survival of tumor cells expressing relatively 
high levels of VEGF, which rendered them relatively 
resistant to chemotherapy-induced apoptosis (30). 
In this work, we showed VEGF protein levels were 
significantly lower in the MNU+P-MAPA+Cisplatin 
and in the MNU+P-MAPA+Doxorubicin groups, as 
well as in the MNU+P-MAPA group, indicating 
that P-MAPA immunotherapy was essential in the 
inhibition of angiogenesis process, mainly when 
associated with systemic chemotherapeutic agents.
Although the recommended option in the 
case of BCG failures (e.g BCG refractory and BCG 
relapsing) is to proceed with early cystectomy, a 
conservative therapy must be tried for carefully 
selected patients, without unacceptable risks. In 
a translational perspective, taking into account 
previously published studies (8, 9) and the pres-
ent data, intravesical P-MAPA immunotherapy 
may be considered as a valuable option for treat-
ment of BCG unresponsive patients that unmet 
the criteria for early cystectomy.
For NMIBC patients that are unresponsive 
to BCG and simultaneously are unfit for or refuse 
cystectomy, the use of P-MAPA alone appears 
very promising because the data of this study 
shows that intravesical P-MAPA is clearly supe-
rior (80% responders) to intravesical anthracy-
cline (DOXO) for treatment of high-grade NMIBC.
Finally, it could be concluded that com-
bination of P-MAPA intravesical immunotherapy 
and systemic cisplatin in the NMIBC animal model 
was effective, well tolerated and showed no ap-
parent signs of antagonism between the drugs.
Thus, these findings appears promising 
because permits consider also the investigational 
use of intravesical P-MAPA combined with sys-
temic cisplatin or cisplatin-based combinations 
for treatment of NMIBC patients unresponsive to 
BCG that are unfit for cystectomy due the high 
risk of comorbidities, aiming to fight simultane-
ously intravesical (superficial) and invasive (met-
astatic) lesions, if any, at the time of treatment.
Despite the limitations of the animal mod-
el used, that not provides invasive lesions, the 
data of this work indicate that use of intravesical 
P-MAPA in combination with systemic cisplatin 
or cisplatin-based combinations may be think-
ing for development of combinations aiming the 
conservative treatment of invasive bladder can-
cer to be evaluated in other animal models or 
even as salvage therapy.
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Câncer de Próstata: Efeitos do Imunomodulador P-MAPA. 
International Braz J Urol 2013;39:18.
21. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler 
P, Tannock I, et al. A randomized comparison of cisplatin 
alone or in combination with methotrexate, vinblastine, and 
doxorubicin in patients with metastatic urothelial carcinoma: 
a cooperative group study. J Clin Oncol. 1992;10:1066-73. 
Erratum in: J Clin Oncol 1993;11:384.
22. Roberts JT, von der Maase H, Sengeløv L, Conte PF, Dogliotti 
L, Oliver T, et al. Long-term survival results of a randomized 
trial comparing gemcitabine/cisplatin and methotrexate/
vinblastine/doxorubicin/cisplatin in patients with locally 
advanced and metastatic bladder cancer. Ann Oncol. 
2006;17:v118-22. Retraction in: Ann Oncol. 2011;22:2536.
23. Zhang XY, Li WG, Wu YJ, Gao MT. Amelioration of doxorubicin-
induced myocardial oxidative stress and immunosuppression 
by grape seed proanthocyanidins in tumour-bearing mice. J 
Pharm Pharmacol. 2005;57:1043-52.
ibju | Immunotherapy and Chemotherapy on Bladder CanCer
954
24. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang 
X, Shen TH, Matos T, et al. Inactivation of p53 and 
Pten promotes invasive bladder cancer. Genes Dev. 
2009;23:675-80.
25. Kohn KW, Pommier Y. Molecular interaction map of the p53 
and Mdm2 logic elements, which control the Off-On switch 
of p53 in response to DNA damage. Biochem Biophys Res 
Commun. 2005;331:816-27.
26. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: 
the PI3K pathway as an integrator of multiple inputs during 
tumorigenesis. Nat Rev Cancer. 2006;6:184-92.
27. Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN 
sensitizes human ovarian cancer cells to cisplatin-induced 
apoptosis in a p53-dependent manner. Gynecol Oncol. 
2006;102:348-55.
28. Meng Q, Peng Z, Chen L, Si J, Dong Z, Xia Y. Nuclear Factor-
κB modulates cellular glutathione and prevents oxidative 
stress in cancer cells. Cancer Lett. 2010;299:45-53.
29. Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial 
cell metabolism: parallels and divergences with cancer cell 
metabolism. Cancer Metab. 2014;2:19.
30. Inoue T, Kibata K, Suzuki M, Nakamura S, Motoda R, Orita K. 
Identification of a vascular endothelial growth factor (VEGF) 
antagonist, sFlt-1, from a human hematopoietic cell line 
NALM-16. FEBS Lett. 2000;469:14-8.
_______________________
Correspondence address:
Wagner José Fávaro, PhD
Laboratório de Urogenital Carcinogênese e Imunoterapia
Universidade de Campinas (UNICAMP)
P.O. BOX 6109
Campinas, Sao Paulo, 13083-865, Brazil
Telephone: +55 19 3521-6104
E-mail: wjfavaro@gmail.com
